8-K/A: C4 Therapeutics Appoints New Chief Scientific Officer Following Retirement of Long-Term Leader

C4 Therapeutics has appointed Paige Mahaney as its new Chief Scientific Officer, succeeding Stewart Fisher who is retiring but will remain as a consultant.

Summary

• C4 Therapeutics announced the appointment of Paige Mahaney as Chief Scientific Officer, effective October 28, 2024.
• This appointment follows the retirement of Stewart Fisher, the previous CSO, who will transition to a Senior Scientific Advisor role until December 31, 2024, and then serve as a consultant through December 31, 2025.
• Dr. Mahaney joins from Exelixis, where she was responsible for drug discovery strategy and advancing the early clinical pipeline.
• She has over 25 years of experience in pharmaceutical and biotech leadership, including roles at Boehringer Ingelheim, Hoffman-La Roche, and Wyeth Pharmaceuticals.
• Dr. Mahaney's compensation includes a $510,000 annual base salary, a $150,000 sign-on bonus, a relocation allowance of up to $75,000, and a potential annual performance bonus of up to 40% of her base salary.
• She will also receive stock options for 345,600 shares and restricted stock units for 76,800 shares, vesting over time.
• Dr. Fisher's departure is not due to any disagreements with the company's operations, policies, or practices.
• He will continue to vest his equity awards through December 31, 2025, as part of his consulting agreement.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the appointment of a highly qualified new CSO and a smooth transition plan with the retiring CSO. The company is clearly positioning itself for future growth and success.

Positives

• The appointment of Paige Mahaney brings a highly experienced leader with over 25 years in pharmaceutical and biotech, including significant experience in drug discovery and clinical portfolio expansion.
• Dr. Mahaney's background includes successful roles at Exelixis and Boehringer Ingelheim, where she advanced multiple candidates to clinical trials.
• The transition plan ensures continuity with Stewart Fisher remaining as a consultant through 2025, providing valuable expertise and guidance.
• The company is providing a competitive compensation package to attract top talent like Dr. Mahaney.

Negatives

• The departure of Stewart Fisher, who has been with the company since 2016 and CSO since 2018, could represent a loss of institutional knowledge.
• There is a transition period where the company will have to manage the change in leadership.

Risks

• The transition of leadership in a key role like CSO could pose some risks to the company's ongoing research and development efforts.
• There is a risk that the new CSO's strategies may not align perfectly with the company's existing plans.
• The company's future success depends on the successful integration of the new CSO and her ability to continue the progress made by her predecessor.

Future Outlook

The company expects Paige Mahaney to leverage her experience to further investigate the promise of targeted protein degradation and extend the company's leadership in the field. The company also expects to continue to benefit from Stewart Fisher's expertise through his consulting role.

Management Comments

• Andrew Hirsch, president and chief executive officer of C4 Therapeutics, expressed excitement about welcoming Paige Mahaney and gratitude to Stewart Fisher for his contributions.
• Paige Mahaney stated she was drawn to C4T because of the demonstrated ability of the TORPEDO platform to deliver degrader candidates.
• Stewart Fisher expressed his honor to have worked at C4 Therapeutics and excitement about the company's future with Paige Mahaney's leadership.

Industry Context

This announcement reflects the ongoing trend of leadership changes in the biotech industry as companies evolve and seek to bring in new expertise. The appointment of a CSO with a strong background in drug discovery and clinical development is crucial for companies focused on advancing their pipelines.

Comparison to Industry Standards

• The compensation package for Dr. Mahaney, including a base salary of $510,000, a sign-on bonus of $150,000, and potential performance bonuses, is competitive with industry standards for a Chief Scientific Officer role at a clinical-stage biopharmaceutical company.
• The stock option and RSU grants are also typical incentives used to attract and retain top executive talent in the biotech sector.
• Companies like Exelixis and Boehringer Ingelheim, where Dr. Mahaney previously held leadership positions, are known for their strong drug discovery and development programs, suggesting that her experience aligns well with industry best practices.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of a new CSO with optimism, potentially leading to increased investor confidence.
• Employees may experience a change in leadership and potentially new strategic directions.
• Customers and partners may expect continued innovation and progress in the company's drug development programs.
• Suppliers and creditors may not be significantly impacted by this change.

Next Steps

• Paige Mahaney will assume her role as Chief Scientific Officer on October 28, 2024.
• Stewart Fisher will transition to a Senior Scientific Advisor role until December 31, 2024, and then serve as a consultant through December 31, 2025.
• The company will continue to advance its targeted oncology programs and leverage its TORPEDO platform.

Key Dates

Keywords

Chief Scientific Officer, CSO, Paige Mahaney, Stewart Fisher, C4 Therapeutics, Targeted Protein Degradation, Drug Discovery, Biopharmaceutical, Retirement, Consulting Agreement